Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Express Scripts
Medtronic
Mallinckrodt
Harvard Business School

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for LY03005

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug LY03005: Sponsors, patents, clinical trial progress

LY03005 is an investigational drug.

There have been 7 clinical trials for LY03005. The most recent clinical trial was a Phase 1 trial, which was initiated on November 27th 2017.

The most common disease conditions in clinical trials are Depressive Disorder, Major, Depressive Disorder, and Depression. The leading clinical trial sponsors are Luye Pharma Group Ltd., Shandong Luye Pharmaceutical Co., Ltd., and [disabled in preview].

There are four US patents protecting this investigational drug and forty-three international patents.

Recent Clinical Trials for LY03005
TitleSponsorPhase
A Relative Bioavailability Food Effect Study of LY03005Luye Pharma Group Ltd.Phase 1
A Cross-over Relative Bioavailability (RBA) Study of LY03005 vs PristiqLuye Pharma Group Ltd.Phase 1
Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®Luye Pharma Group Ltd.Phase 1

See all LY03005 clinical trials

Clinical Trial Summary for LY03005

Top disease conditions for LY03005
Top clinical trial sponsors for LY03005

See all LY03005 clinical trials

US Patents for LY03005

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LY03005   Start Trial Compounds for inhibition of 5-hydroxytryptamine and norepinephrine reuptake or for treatment of depression disorders, their preparation processes and uses thereof Shandong Luye Pharmaceutical Co., Ltd. (Yantai, Shandong, CN) Li; Youxin (Zhuzhou, Hunan, CN)   Start Trial
LY03005   Start Trial Compounds for inhibition of 5-hydroxytryptamine and norepinephrine reuptake or for treatment of depression disorders, their preparation processes and uses thereof Shandong Luye Pharmaceutical Co. Ltd. (Yantai, CN) Li; Youxin (Zhuzhou, CN)   Start Trial
LY03005   Start Trial Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methyl-benzoate hydrochloride, methods for preparing the same and use of the same Shangong Luye Pharmaceutical Co., Ltd. (Yantai, Shandong, CN) Li; Youxin (Langenfeld, DE)   Start Trial
LY03005   Start Trial Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods of preparing the same and use of the same SHANDONG LUYE PHARMACEUTICAL CO., LTD. (Yantai, CN) Li; Youxin (Langenfield, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Baxter
Merck
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.